Solrom and AHM: The Larger Acquisition Brings Debt Back to the Center
AHM is Solrom's main 2026 scale event: a profitable company with about NIS 34.9 million of unaudited backlog, but also an acquisition funded with new debt and deferred consideration. The near-term proof is not the deal itself, but whether AHM's backlog and gross margin enter Solrom's accounts as cash-generating activity.
Solrom Holdings did not buy just another bolt-on activity. AHM is the acquisition that brings debt back to the center after a quarter in which the company had actually repaid credit and increased its cash balance. In operating scale, this is the deal that can change the revenue pace already from the second quarter: AHM showed unaudited 2025 revenue of NIS 26.7 million, gross profit of NIS 9.9 million and backlog of about NIS 34.9 million near signing. In capital-structure terms, it is also a deal that pulls in NIS 16 million of new loans, NIS 7 million of deferred consideration and up to NIS 7 million of contingent consideration before investors have seen one shekel of consolidated cash flow from the acquired activity. The current conclusion is cautiously constructive: if AHM's gross margin and backlog survive inside the group, the new debt can be a reasonable price for expanding a defense-industrial platform. If revenue meets the earnout thresholds but collections, margin or integration weaken, the acquisition may increase scale faster than it improves business quality.
The Acquisition Is Large Relative to the Cash Base
The starting number is not only the acquisition price, but the relationship between that price and liquidity just before closing. At the end of March, cash was NIS 7.1 million, after NIS 3.0 million of operating cash flow and NIS 11.1 million from option exercises, but also after about NIS 8 million of net credit repayment. In April, the company paid a NIS 4.35 million dividend. In May came the AHM acquisition, with NIS 16 million of cash paid at closing and funded through two new loans at prime plus 1.1%.
The note breaks down NIS 33.9 million of non-discounted consideration: NIS 16 million in cash, NIS 7 million of deferred consideration, up to NIS 7 million of contingent consideration and 411,765 shares valued in the table at NIS 3.9 million. The investor presentation presents the transaction as up to NIS 37 million, because the value of the share consideration will ultimately be determined by the share price at the allocation date. That is a small detail, but it reminds readers that the final cost is not yet a fully settled number.
| AHM Deal Component | Figure | Why It Matters |
|---|---|---|
| Non-discounted consideration | NIS 33.9 million | A meaningful price relative to the March-end cash balance |
| New loans to fund the deal | NIS 16 million | Debt enters immediately, before the acquired activity appears in consolidated results |
| 2025 revenue and gross profit | NIS 26.7 million and NIS 9.9 million | On unaudited figures, the price looks reasonable only if this margin holds |
| Backlog near signing | About NIS 34.9 million | About NIS 20 million is scheduled for delivery in 2026, so the proof is near term |
Based on the unaudited 2025 figures alone, the non-discounted consideration is roughly 5.7 times AHM's 2025 net profit. That does not look disconnected if profitability holds, but that is exactly the important caveat: the figures were provided to the company by AHM, have not yet been reviewed by the company and are unaudited. The purchase price allocation to assets, liabilities and contingent liabilities has also not yet been completed because the transaction was signed close to approval of the financial statements.
The Earnout Tests Revenue, Not Cash Quality
The contingent consideration mechanism shows what AHM's former shareholder needs to prove in order to receive additional payment. If AHM's 2026 sales exceed NIS 26 million, the seller will be entitled to additional consideration of NIS 1 million to NIS 4 million. If sales in the first half of 2027 exceed NIS 13 million, the seller will be entitled to another NIS 1 million to NIS 3 million.
Those are not remote thresholds relative to the disclosed figures. AHM already showed NIS 26.7 million of revenue in 2025, and in the first quarter of 2026 it showed NIS 7.7 million of revenue and NIS 1.8 million of net profit. Backlog near signing was about NIS 34.9 million, of which about NIS 20 million is scheduled for delivery in 2026 and the rest in 2027. If those figures convert at a reasonable pace, the contingent consideration can become a real cash cost rather than a footnote.
This is the yellow flag. The earnout is tied to revenue, while what investors need the company to prove is margin, collection and debt service capacity. AHM's gross margin was 37.3% in 2025 and 46.4% in the first quarter of 2026, but both figures are unaudited. If those margins hold after the acquisition, the deal adds manufacturing capability and profitability that can also support the QCL activity. If they erode, the company may pay additional consideration for sales volume without receiving the same cash quality.
The Acquired Backlog Needs to Become Collections
On an all-in cash flexibility basis after actual cash uses, the first quarter did not leave the company with a large surplus before the acquisitions. Operating cash flow was NIS 3.0 million, but receivables fell mainly because of a NIS 9.5 million factoring transaction. At the same time, inventory increased by NIS 3.3 million and contract assets increased by NIS 1.5 million. The quarter therefore improved liquidity, but it did not yet prove that defense growth funds itself without working-capital financing tools.
AHM can improve that picture precisely because its backlog is relatively close to revenue. About NIS 20 million of the backlog is scheduled for delivery in 2026, so the coming quarters should show quickly whether the acquired business is actually producing profit and cash. That is also what separates it from an early-stage technology story: this is not only future optionality, but an existing activity with a plant, employees, revenue and net profit. Because the debt and deferred payments are already known, however, the proof cannot stop at the revenue line.
What Will Decide AHM
The AHM verdict will sharpen quickly. If the unaudited backlog converts into revenue at the presented pace, if gross margin stays close to 2025 levels, and if collections support debt service and deferred consideration, the acquisition will look like an expansion of industrial capability at a price that can be justified. If the company mainly shows higher revenue without better cash flow and without clearer disclosure on post-integration margin, the new debt will carry more weight than the synergy narrative. The next proof point is not another backlog slide, but consolidated financial statements showing whether AHM remains profitable and cash-generative inside the group.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.